Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.53 EUR | +1.92% |
|
-22.06% | 0.00% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.65 for the 2024 fiscal year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 587M | - | ||
+16.80% | 43.26B | B- | ||
+17.47% | 21.6B | B+ | ||
+21.62% | 15.93B | - | ||
+23.95% | 15.1B | B+ | ||
+57.96% | 12.95B | B | ||
-0.05% | 6.79B | - | - | |
-16.22% | 6.29B | B+ | ||
+19.77% | 6.04B | B+ | ||
-8.87% | 5.73B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 1681 Stock
- C1P Stock
- Ratings Consun Pharmaceutical Group Limited